Last reviewed · How we verify

NCT06331260

Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma

Not yet recruiting Last updated 26 March 2024
What this trial tests

trial in Liver Transplantation in 600 participants. Not yet recruiting.

Timeline
1 April 2024
Primary endpoint
1 April 2028
1 April 2028

Quick facts

Lead sponsorZhejiang University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment600
Start date1 April 2024
Primary completion1 April 2028
Estimated completion1 April 2028

Conditions studied

Sponsor

Zhejiang University

Who can join

18 and older, any sex, with Liver Transplantation or Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As key biomarkers in HCC, AFP and PIVKA-II reflects biological features of tumor and has been widely applied for clinical diagnosis. Previous studies reported preoperative AFP and PIVKA-II are related to HCC recipient long-term survival after liver transplantation. However, there is no prospective study supporting these conclusions. This study aims to prospective collect liver transplantation cases from multiple transplant centers and further evaluate the prognostic role of preoperative AFP and PIVKA-II in liver transplantation for HCC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

Other Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06331260.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing